Rocket Pharmaceuticals (RCKT) Capital Leases (2020 - 2026)

Rocket Pharmaceuticals has disclosed Capital Leases across 7 years of filings, most recently posting $19.3 million for Q1 2026.

• Capital Leases for Q1 2026 came in at $19.3 million, changed 0.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.3 million (changed 0.18% YoY), and the FY2025 annual result was $19.4 million, changed 0.11% from the prior year.
• Capital Leases came in at $19.3 million for Q1 2026 at Rocket Pharmaceuticals, roughly flat from $19.4 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $19.4 million in Q4 2024 to a low of $19.2 million in Q1 2022.
• The 5-year median for Capital Leases is $19.4 million (2023), against an average of $19.3 million.
• Across the five-year window, Capital Leases increased 0.78% in 2022 and retreated 0.18% in 2026, its largest moves.
• Rocket Pharmaceuticals' Capital Leases stood at $19.3 million in 2022, then climbed by 0.44% to $19.4 million in 2023, then grew by 0.16% to $19.4 million in 2024, then retreated by 0.11% to $19.4 million in 2025, then fell by 0.08% to $19.3 million in 2026.
• The last three Capital Leases figures came in at $19.3 million (Q1 2026), $19.4 million (Q4 2025), and $19.4 million (Q3 2025), per Business Quant data.